There are no FDA-approved treatments for anti-N-methyl-d-aspartate receptor encephalitis (NMDARE), and no prospective, multicenter clinical trials have been completed to provide evidence for management of this disease.
We evaluated changes in treatment strategies and outcomes since the previous comprehensive review in 2019.
